80965-30-6

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(4-methylpiperidino)pyridine serves as a crucial building block in the creation of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications, contributing to advancements in medicinal chemistry.
Used in Organic Compounds Synthesis:
Beyond its pharmaceutical applications, 4-(4-methylpiperidino)pyridine is also utilized in the synthesis of a range of organic compounds. Its reactivity and structural features make it a valuable component in organic chemistry for creating complex molecules with specific properties.
Used in Chemical Research:
In the field of chemical research, 4-(4-methylpiperidino)pyridine is employed as a model compound to study various chemical reactions and mechanisms. Its presence in experiments can provide insights into the behavior of similar compounds and contribute to a deeper understanding of organic chemistry principles.
Used in Drug Development:
4-(4-methylpiperidino)pyridine plays a pivotal role in drug development, where its structural attributes can be leveraged to design and optimize the pharmacological properties of new drug candidates. Its versatility in chemical reactions facilitates the exploration of novel therapeutic agents.

Upstream product

• 626-58-4 4-methylpiperidin 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 100-48-1 pyridine-4-carbonitrile 

Downstream Products

• 1823-59-2 4,4'-oxydiphthalic dianhydride 

Relevant academic research and scientific papers

SELECTIVE INHIBITORS AND ALLOSTERIC ACTIVATORS OF SPHINGOSINE KINASE

Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of S1P, may be useful anti- proliferative agents. We have synthesized a series of sphingosine-based inhibitors of SK and SK2. Also provided in this invention are compounds that activate SK1 which can be used in diseases such as fibrosis, where intracellular S1P is anti-fibrotic.

Structure-Activity relationships and molecular modeling of sphingosine kinase inhibitors

The design, synthesis, and evaluation of the potency of new isoform-selective inhibitors of sphingosine kinases 1 and 2 (SK1 and SK2), the enzyme that catalyzes the phosphorylation of d-erythro-sphingosine to produce the key signaling lipid, sphingosine 1-phosphate, are described. Recently, we reported that 1-(4-octylphenethyl)piperidin-4-ol (RB-005) is a selective inhibitor of SK1. Here we report the synthesis of 43 new analogues of RB-005, in which the lipophilic tail, polar headgroup, and linker region were modified to extend the structure-activity relationship profile for this lead compound, which we explain using modeling studies with the recently published crystal structure of SK1. We provide a basis for the key residues targeted by our profiled series and provide further evidence for the ability to discriminate between the two isoforms using pharmacological intervention.

Synthesis of aminopyridines via an unprecedented nucleophilic aromatic substitution of cyanopyridines

The direct reaction of 2- and 4-cyanopyridines with lithium amides affords good yields of the corresponding aminopyridines via displacement of cyanide. Addition of CsF accelerates the reaction and can lead to significantly higher yields.